Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 99.80B -23.4% |
| Revenue (ttm) | 46.72B +5.5% |
| Net Income | 7.81B +40.5% |
| EPS | 6.40 +44.2% |
| Shares Out | 1.21B |
| PE Ratio | 20.40 |
| Forward PE | 9.87 |
| Dividend | 4.12 (5.01%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 3,602,831 |
| Average Volume | 2,295,061 |
| Open | 82.94 |
| Previous Close | 82.56 |
| Day's Range | 77.34 - 82.95 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.37 |
| RSI | 46.30 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Sanofi (SNY) Appoints Belen Garijo as Incoming CEO
Sanofi (SNY) Appoints Belen Garijo as Incoming CEO
Leadership Change Announced for Sanofi (SNY)
Leadership Change Announced for Sanofi (SNY)
Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'
Sanofi SA (NASDAQ: SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson . As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his ...
Who is Sanofi's new CEO Belén Garijo?
French drugmaker Sanofi on Thursday appointed Belén Garijo as its new chief executive after choosing not to renew the mandate of Paul Hudson.
Sanofi (SNY) Appoints New CEO, Belén Garijo, to Lead Future Strategy
Sanofi (SNY) Appoints New CEO, Belén Garijo, to Lead Future Strategy
Sanofi CEO Paul Hudson To Depart; Belén Garijo Named Successor
(RTTNews) - Sanofi (SAN.PA, SNY), a French pharmaceutical and healthcare company, on Thursday announced that the Board of Directors had decided not to renew the director mandate of Chief Executive Off...
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate
French drugmaker Sanofi said on Thursday it had appointed Belén Garijo as its new chief executive after deciding not to renew the mandate of current CEO Paul Hudson.
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson.
Sanofi Breaks Above 200-Day Moving Average - Bullish for SNY
In trading on Wednesday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $49.14, changing hands as high as $49.42 per share. Sanofi shares are currently trading up about 1...
Sanofi (SNY) Invests $30M in GluBio for Sickle Cell Disease Research
Sanofi (SNY) Invests $30M in GluBio for Sickle Cell Disease Research
Sanofi: Information concerning the total number of voting rights and shares – January 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sanofi makes $30M investment in Chinese biotech GluBio
Sanofi (SNY) Finalizes Acquisition of Dynavax to Enhance Vaccine Portfolio
Sanofi (SNY) Finalizes Acquisition of Dynavax to Enhance Vaccine Portfolio
Press Release: Sanofi completes the acquisition of Dynavax
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax).
Sanofi (SNY) Faces Legal Challenges Amid Patent Disputes
Sanofi (SNY) Faces Legal Challenges Amid Patent Disputes
Sanofi CEO: The enterprise AI shift will reshape pharma in 2026
At Sanofi, AI has shifted from experimentation to becoming a vital part of our infrastructure.
Sanofi (SNY) Collaborates on New Allergy Treatment Insights
Sanofi (SNY) Collaborates on New Allergy Treatment Insights
Sanofi (SNY) Achieves Breakthrough Designation for Rilzabrutinib
Sanofi (SNY) Achieves Breakthrough Designation for Rilzabrutinib
Sanofi’s rilzabrutinib gains breakthrough therapy status in US, orphan drug designation in Japan
Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi...
Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells
Oakmark International Strategy Q4 2025 New Investments And Divestments
Oakmark International Strategy Q4 2025 New Investments And Divestments
Sanofi (SNY) Announces â¬1B Share Buyback Program
Sanofi (SNY) Announces â¬1B Share Buyback Program
Sanofi Signs Mandate For EUR 1 Bln Share Buyback
(RTTNews) - Sanofi (SNY, SAN.PA), a French pharmaceutical and healthcare company, on Monday said it has signed a mandate to execute a 1 billion euros share buyback program in 2026.